Julia Taylor, PA
Medical · Spokane, WANPI 1336248129
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,495 of the $12,130 with a category attached, or 86.5%. 26 manufacturers reported payments, led by AbbVie at 28.2% of the total. Among medical clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 545 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$3K
- Lilly USA, LLC$1K
- Pfizer$844
- Amgen$628
- UCB, Inc.$588
- plus $3K from 20 others
What the payments were for
- Consulting fees$1,0639%
- Food & beverage$10,49587%
- Education$5735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 191 | $3,426 |
| Johnson & Johnson | 81 | $2,659 |
| Lilly USA, LLC | 46 | $1,083 |
| Pfizer | 46 | $844 |
| Amgen | 37 | $628 |
| UCB, Inc. | 24 | $588 |
| E.r. Squibb & Sons, L.L.C. | 25 | $533 |
| Sun Pharmaceutical Industries Inc. | 16 | $491 |
| Regeneron Healthcare Solutions, Inc. | 13 | $401 |
| Merz North America, Inc. | 11 | $247 |
| Janssen Scientific Affairs, LLC | 3 | $179 |
| Novartis | 7 | $147 |
| Incyte Corporation | 7 | $137 |
| LEO Pharma Inc. | 6 | $132 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $128 |
| Dermavant Sciences, Inc. | 4 | $116 |
| Biofrontera Inc. | 4 | $92 |
| Galderma Laboratories, L.p. | 5 | $87 |
| Genentech USA, Inc. | 3 | $55 |
| Sanofi | 2 | $42 |
| Blueprint Medicines Corporation | 1 | $27 |
| Krystal Biotech Inc | 1 | $23 |
| Organon | 2 | $22 |
| Organogenesis Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
| Biowound Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,130 in reported general payments places this provider in the 95th percentile of 457 medical providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $225,012 |
| Dupixent PenDupilumab | 28 | $102,880 |
| OtezlaApremilast | 19 | $89,361 |
| Taltz AutoinjectorIxekizumab | 11 | $73,953 |
| Clobetasol Propionate | 60 | $2,260 |
| Metronidazole | 30 | $1,542 |
| Tretinoin | 11 | $1,182 |
| Doxycycline Hyclate | 15 | $617 |
| Clindamycin Phosphate | 16 | $472 |
| Ketoconazole | 17 | $436 |
| ValacyclovirValacyclovir Hcl | 13 | $231 |
| Triamcinolone Acetonide | 27 | $201 |
| Spironolactone | 20 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $628 | $89,36119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 medical providers in Washington.
Other medical in Spokane
- Rebecca JohnsonSpokane$14K
- Kristine WesselsSpokane$10K
- Kyle RoblesSpokane$8K
- David BacaSpokane$8K
- Zachary StilesSpokane$7K
- Abigail KlemmeSpokane$7K
- Justin OverhoffSpokane$5K
- Alena IzhokhinaSpokane$4K
- Diana McFarlaneSeattle$95K
- Karissa SecoraTacoma$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.